The generic drug manufacturing company from India, Sun Pharmaceutical Industries Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to sell a generic version of AstraZeneca's prostate cancer drug Casodex. Casodex (bicalutamide) is an anti-androgen that block the ability of androgens (testosterone) to access the prostate cancer cell and “fuel” them. Used [...]
Selenium is one of those supplements that were are told is good for us and then we are told it is bad for us. Every six months to a year the story and the recommendations seem to change. According to a study by researchers at Dana-Farber Cancer Institute the University of California, San Francisco higher [...]
The FDA did introduce its Critical Path initiative in 2004. But, even these expedited processes have become bogged down. The FDA has responded to the political winds and become cautious after the negative publicity it received from the withdrawals of drugs like Rezulin and Vioxx. The best and most recent delay in the prostate cancer [...]
Senator Arlen Specter (D-PA) introduced S. 914, the Cures Acceleration Network and National Institutes of Health Reauthorization Act of 2009. The bill has three main components: 1. Establishes a new, independent federal agency, to be known as the “Cures Acceleration Network” (CAN), which would award grants and contracts to accelerate the development of cures and [...]
A presentation at the ASCO conference in Florida reconfirmed the fact that increased levels of C-reactive protein (CRP) is associated with adverse outcomes (earlier death) in men with castration-resistant prostate cancer (CRPC) treated with docetaxel (taxotere). The study analyzed the baseline serum samples from 119 castrate resistant (CRPC) men enrolled in 6 phase I or [...]